136 related articles for article (PubMed ID: 4509140)
21. Timed sequential therapy of acute leukemia with flavopiridol: in vitro model for a phase I clinical trial.
Karp JE; Ross DD; Yang W; Tidwell ML; Wei Y; Greer J; Mann DL; Nakanishi T; Wright JJ; Colevas AD
Clin Cancer Res; 2003 Jan; 9(1):307-15. PubMed ID: 12538483
[TBL] [Abstract][Full Text] [Related]
22. Heterogeneity of isolated mononuclear cells from patients with acute myeloid leukemia affects cellular accumulation and efflux of daunorubicin.
Knaust E; Porwit-MacDonald A; Gruber A; Xu D; Peterson C
Haematologica; 2000 Feb; 85(2):124-32. PubMed ID: 10681718
[TBL] [Abstract][Full Text] [Related]
23. Studies on myelocytic cell turnover in bone marrow and blood.
Fliedner TM; Cronkite EP; Bond VP
Nucl Med (Stuttg); 1963; 2():Suppl 1:279-94. PubMed ID: 5900122
[No Abstract] [Full Text] [Related]
24. [In vitro proliferation of leukemic blast cells and response to daunorubidomycin-cytosine arabinoside].
Huber H; Huber CH; Michlmayr G; Asamer H; Braunsteiner H
Schweiz Med Wochenschr; 1971 Dec; 101(49):1785-7. PubMed ID: 5140917
[No Abstract] [Full Text] [Related]
25. Bone marrow morphology during induction phase of therapy for acute myeloid leukemia (AML).
Dick FR; Burns CP; Weiner GJ; Heckman KD
Hematol Pathol; 1995; 9(2):95-106. PubMed ID: 7559259
[TBL] [Abstract][Full Text] [Related]
26. High-dose daunorubicin therapy for acute nonlymphocytic leukemia: correlation of response and toxicity with pharmacokinetics and intracellular daunorubicin reductase activity.
Greene W; Huffman D; Wiernik PH; Schimpff S; Benjamin R; Bachur N
Cancer; 1972 Dec; 30(6):1419-27. PubMed ID: 4264560
[No Abstract] [Full Text] [Related]
27. Mechanism of eosinophilia. V. Kinetics of normal and accelerated eosinopoiesis.
Spry CJ
Cell Tissue Kinet; 1971 Jul; 4(4):351-64. PubMed ID: 5127358
[No Abstract] [Full Text] [Related]
28. Factors in human serum affecting the proliferation of normal and leukemic cells.
Burke PJ; Diggs CH; Owens AH
Cancer Res; 1973 Apr; 33(4):800-6. PubMed ID: 4512147
[No Abstract] [Full Text] [Related]
29. Perturbation of cell cycle of human leukaemic myeloblasts in vivo by cytosine arabinoside.
Ernst P; Faille A; Killmann SA
Scand J Haematol; 1973; 10(3):209-18. PubMed ID: 4520466
[No Abstract] [Full Text] [Related]
30. Kinetics of normal and leukemic leukocyte populations and relevance to chemotherapy.
Skipper HE; Perry S
Cancer Res; 1970 Jun; 30(6):1883-97. PubMed ID: 4917694
[No Abstract] [Full Text] [Related]
31. The effect of daunomycin on human cells in vivo and in vitro.
Whang-Peng J; Leventhal BG; Adamson JW; Perry S
Cancer; 1969 Jan; 23(1):113-21. PubMed ID: 5249421
[No Abstract] [Full Text] [Related]
32. Effect of cytostatic drugs on the kinetics of leukemic blast cells in man.
Killmann SA
Schweiz Med Wochenschr; 1974 Feb; 104(8):278-84. PubMed ID: 4814680
[No Abstract] [Full Text] [Related]
33. Return of human leukemic myeloblasts from blood to bone marrow.
Killmann SA; Karle H; Ernst P; Andersen V
Acta Med Scand; 1971; 189(1-2):137-42. PubMed ID: 5287315
[No Abstract] [Full Text] [Related]
34. DNA synthesis in leukemic cells under the action of cytotoxic agents in vitro and in vivo.
Wilmanns W
Natl Cancer Inst Monogr; 1971 Dec; 34():153-9. PubMed ID: 5291099
[No Abstract] [Full Text] [Related]
35. In vitro proliferation of normal and leukaemic human leukocytes controlled by an inhibitory endopeptide.
Balázs A; Mann J; Takácsi-Nagy L; Zimonyi I; Molnár A; Klupp T
Folia Haematol Int Mag Klin Morphol Blutforsch; 1983; 110(1):24-31. PubMed ID: 6192050
[TBL] [Abstract][Full Text] [Related]
36. Impact of in vivo administration of interleukin 3 on proliferation, differentiation, and chemosensitivity of acute myeloid leukemia.
Gore SD; Weng LJ; Jones RJ; Cowan K; Zilcha M; Piantadosi S; Burke PJ
Clin Cancer Res; 1995 Mar; 1(3):295-303. PubMed ID: 9815985
[TBL] [Abstract][Full Text] [Related]
37. 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group.
Büchner T; Hiddemann W; Berdel WE; Wörmann B; Schoch C; Fonatsch C; Löffler H; Haferlach T; Ludwig WD; Maschmeyer G; Staib P; Aul C; Gruneisen A; Lengfelder E; Frickhofen N; Kern W; Serve HL; Mesters RM; Sauerland MC; Heinecke A;
J Clin Oncol; 2003 Dec; 21(24):4496-504. PubMed ID: 14673036
[TBL] [Abstract][Full Text] [Related]
38. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
Walker AR; Komrokji RS; Ifthikharuddin J; Messina P; Mulford D; Becker M; Friedberg J; Oliva J; Phillips G; Liesveld JL; Abboud C
Leuk Res; 2008 Dec; 32(12):1830-6. PubMed ID: 18571721
[TBL] [Abstract][Full Text] [Related]
39. [Leukemic bone marrow stromal cells in vitro protect leukemic cell line Jurkat cells from daunorubicin-induced apoptosis].
Li ZJ; Teng BX; Chen XH; Kong PY; Wang JG; Peng XG; Yang ZZ
Ai Zheng; 2005 Jun; 24(6):672-5. PubMed ID: 15946476
[TBL] [Abstract][Full Text] [Related]
40. In vitro DNA labeling of bone marrow and leukemic blood leukocytes with tritiated thymidine. II. H3 thymidine biochemistry in vitro.
Rubini JR
J Lab Clin Med; 1966 Oct; 68(4):566-76. PubMed ID: 5923249
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
